Association of obstructive sleep apnea and diurnal variation of cystatin C
- PMID: 38287274
- PMCID: PMC10823701
- DOI: 10.1186/s12882-024-03472-7
Association of obstructive sleep apnea and diurnal variation of cystatin C
Abstract
Purpose: Obstructive sleep apnea is a known risk factor for the progression of chronic kidney disease. To find early signs of the progression in subjects with obstructive sleep apnea., we assessed the diurnal variation of kidney biomarkers.
Methods: A prospective observational study was conducted at Kangwon National University Hospital, Chuncheon, South Korea. All participants underwent in-laboratory polysomnography and phlebotomy in the evening before the polysomnography and in the morning after the polysomnography. Kidney biomarkers, including serum creatinine, blood urea nitrogen, and serum cystatin C, were measured. Delta kidney biomarkers were calculated by subtracting the evening level of the biomarkers from the morning level.
Results: Twenty-six of 50 participants had severe obstructive sleep apnea. Delta cystatin C was significantly correlated with apnea-hypopnea index, oxygen desaturation index, and total arousal index with coefficients of -0.314, -0.323, and -0.289, respectively. In participants without severe obstructive sleep apnea, the morning cystatin C level (0.84 ± 0.11 mg/L) was significantly higher than the evening cystatin C level (0.81 ± 0.11 mg/L) (P = 0.005). With severe obstructive sleep apnea, the cystatin C levels were not different between the morning (0.85 ± 0.11 mg/L) and the evening (0.85 ± 0.10 mg/L).
Conclusions: Cystatin C level was increased in the morning in participants without severe obstructive sleep apnea, but not in participants with severe obstructive sleep apnea.
Keywords: Chronic kidney disease; Circadian rhythm; Cystatin C; Diurnal variation; Nocturnal hypertension; Obstructive sleep apnea.
© 2024. The Author(s).
Conflict of interest statement
Competing interests. The authors declare no competing interests.
Figures

Similar articles
-
Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea.Cochrane Database Syst Rev. 2015 Jul 14;(7):CD011090. doi: 10.1002/14651858.CD011090.pub2. Cochrane Database Syst Rev. 2015. PMID: 26171909
-
Screening Strategies for Sleep-Disordered Breathing in Patients With Spinal Cord Injury in a Tertiary Care Rehabilitation Center.Respir Care. 2024 Aug 24;69(9):1116-1128. doi: 10.4187/respcare.11726. Respir Care. 2024. PMID: 38889927
-
Prospective crossover trial of positional and CPAP therapy for the treatment of mild-to-moderate positional obstructive sleep apnea.J Clin Sleep Med. 2025 Feb 1;21(2):305-313. doi: 10.5664/jcsm.11378. J Clin Sleep Med. 2025. PMID: 39347559 Clinical Trial.
-
Obstructive sleep apnea severity, circulating biomarkers, and cancer risk.J Clin Sleep Med. 2024 Sep 1;20(9):1415-1422. doi: 10.5664/jcsm.11170. J Clin Sleep Med. 2024. PMID: 38648119
-
Drug therapy for obstructive sleep apnoea in adults.Cochrane Database Syst Rev. 2013 May 31;2013(5):CD003002. doi: 10.1002/14651858.CD003002.pub3. Cochrane Database Syst Rev. 2013. PMID: 23728641 Free PMC article.
Cited by
-
Association between elevated cystatin C levels and obstructive sleep apnea hypopnea syndrome: a systematic review and updated meta-analysis.BMC Pulm Med. 2025 Feb 1;25(1):56. doi: 10.1186/s12890-025-03508-0. BMC Pulm Med. 2025. PMID: 39893393 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources